Chronic Pain Clinical Trial
Official title:
Effectiveness and Safety of Oil Extracts Medical Cannabis Treatment for Patients With Chronic Pain: a Web Technology Based Prospective Study
Background: The current study will prospectively follow-up on chronic pain patients treated with oil extracts of medical cannabis (MC) for a period of six months in "real life" conditions. This study will enable a deep investigation regarding the effects of the active extract of cannabis inflorescence formulated in oil, derived from the cannabis plant. The results may allow us to reduce the gap in understanding MC's effects on pain relief and its safety, to identify predictors for treatment success/ failure, as well as to enable us tailoring a personalize MC treatment by choosing optimal concentration and dose according to the patient needs. We hypothesize that following the treatment with oil extracts of MC for chronic pain, associations will be found between its effectiveness and the types of clinical pain, personality traits and demographic characteristics. We also do not expect serious (life threatening) adverse events to be reported. Methods: This study has been already approved by the ethics committee of Haifa University (approval number 216/19). The sample will include a prospective cohort of 600 patients with chronic non-cancer pain that will request license to use oil extracts MC. The patients who will be approved to receive a license will be followed-up longitudinally for a period of six months from the signing of the consent form. The patients will be asked to fill a variety of questionnaires that may indicate the outcome of the treatment. The follow-up will take place in four time points: at the time of approval of the license (before starting the treatment, baseline), as well as at one, three, and six months from the initiation of treatment. Data will be collected by a web based data collection technology (Qualtrics®). In cases which there are a need for it, the information will be gathered by phone or face to face meetings.
The use of medical cannabis (MC) for the treatment of chronic pain has risen in the last
decade. According to the Israel Medical Cannabis Unit (IMCU) of the Israeli Ministry of
Health (IMOH), there are currently several tens of thousands licenses for the use of medical
cannabis in Israel, mostly for the relief of chronic pain (mainly utilized by smoking and
inhalation). It is estimated that 2,000 new licenses will be issued yearly. Recently, the
IMOH approved the use of drops of whole extract of cannabis inflorescence formulated in oil,
intended for sublingual administration, for the treatment of chronic pain. That far, there is
a distinct lack of evidence about the efficacy and safety of MC treatment in the long-term
with relatively few prospective randomized controlled trials (RCTs) examining this issue.
This can be explained, at least partially, by the reluctance of physicians, researchers and
pharmaceutical companies to engage in MC research for various reasons (mainly when utilized
by smoking and inhalation). Such reasons include the following facts: MC is classified as a
schedule I drug by the American Food and Drug Administration (FDA); MC is often smoked; that
the level of cannabinoids and terpenes can vary between suppliers and even from the same
supplier and therefore it is difficult to quantify the dose; there is abuse of MC;
patentability of a natural compounds is problematic; and MC consumption is stigmatized. One
of the accepted ways to narrow gaps of information in medical research where there is a
dearth of RCTs is to develop cohorts that may allow for the prospective, structured data
collection and data mining of a large number of "real life" patient conditions.
The current study will prospectively follow-up on chronic pain patients treated with oil
extracts MC for a period of six months in "real life" conditions. This study will enable a
deep investigation regarding the effects of the active extract of cannabis inflorescence
formulated in oil, derived from the cannabis plant. The results may allow us to reduce the
gap in understanding MC's effects on pain reduction and its safety, to identify predictors
for treatment success/ failure, as well as to enable us tailoring a personalize MC treatment
by choosing optimal concentration and dose according to the patient needs.
Methods: The sample will include a prospective cohort of patients with chronic non-cancer
pain that will request license to use oil extracts medical cannabis. The estimated sample
size is 600 patients. The patients who will be approved to receive a license will be
followed-up longitudinally for a period of six months from the signing of the consent form.
The patients will be recruited by their physicians in their clinics.
Inclusion criteria - Patients that will be recommended to use oil extracts medical cannabis
for the treatment of all forms of chronic pain (despite cancer); Patients above the age of 18
years; Patients who will sign an informed consent after receiving explanation on the
requirements, duration and nature of the study.
Exclusion criteria - Patients who lack the ability to understand the purpose and instructions
of the study.
Questionnaires - (1) Demographic questionnaire includes data regarding age, gender, marital
status, country of origin, religion, weight, height, smoking habitats, and pain etiology; (2)
Co-morbidities; (3) Expectations from cannabis treatment; (4) Information regarding the oil
extracts as: type of the oil, concentration, dose, effect, etc. (5) Patient satisfaction from
the treatment and the information they will be receive; (6) Pain - The short-form McGill Pain
Questionnaire (SF-MPQ), Pain Disability Index (PDI), Pain treatment and other pharmacological
treatments; (7) Pittsburgh Sleep Quality Index (PSQI); (8) Beck Depression Inventory
(BDI-II); (9) Pain Catastrophizing Scale (PCS); (10) General Anxiety Disorder (GAD-7); (11)
Quality of life (EQ5); (12) Changes in appetite; (13) Adverse events - occurrence, severity;
(14) Cognitive status - by a telephone interview.
Study procedure - The study has been approved by the ethics committee of Haifa University
(approval number 216/19). Participants will be recruited by physicians either with pain
management expertise or those who have license to offer MC. Potential patients who will meet
the inclusion criteria, will get a full explanation about the study aims and procedure.
Following their agreement to participate in the study they will sign a written informed
consent that will be sent to the investigator along with the patient's diagnosis and contact
information. Then, the patients will be contacted by the investigator and will be asked to
complete the questionnaires at each of the following time-points: at the time of approval of
the license (before starting the treatment, baseline) a month, three months and six months,
from the initiation of treatment. Data will be collected by a secured web based data
collection technology (Qualtrics®). In case of difficulties in using that technology, the
data will be collected via phone or face to face meetings. Notably, this study is only
observational and not interventional, e.g., the patient will be informed that participation
in this study will not influence the approval\disapproval for the acceptance\renewal of the
oil extract medical cannabis license from the Medical Cannabis Unit (MCU) of the Israeli
health ministry. Additionally, the research related tie between patients to their physician
will be terminated following the signing of the consent form, from this point forward, the
physician will have no access to the specific patients' study related data. This is in
purpose to assure that decisions regarding the patient's further treatments will not be
influenced by any way from the collected data.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|